These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11907436

  • 21. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ.
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z, Zemel R, Kazetsker A, Fraser G, Tur-Kaspa R.
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
    Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Böker KH, Broelsch CE, Pichlmayr R, Manns MP.
    Liver Transpl Surg; 1996 Jul; 2(4):253-62. PubMed ID: 9346658
    [Abstract] [Full Text] [Related]

  • 25. [Prevention and treatment of HBV reinfection following liver transplantation].
    Yuan G, Duan Y, Wang F, Liang S, Zhu L.
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):14-6. PubMed ID: 11856491
    [Abstract] [Full Text] [Related]

  • 26. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
    Seehofer D, Rayes N, Steinmüller T, Müller AR, Settmacher U, Neuhaus R, Radke C, Berg T, Hopf U, Neuhaus P.
    Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
    [Abstract] [Full Text] [Related]

  • 27. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results.
    Berenguer M, Prieto M, Rayón M, Bustamante M, Carrasco D, Moya A, Pastor MA, Gobernado M, Mir J, Berenguer J.
    Am J Gastroenterol; 2001 Feb; 96(2):526-33. PubMed ID: 11232701
    [Abstract] [Full Text] [Related]

  • 28. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation.
    Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X.
    Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):327-9. PubMed ID: 14607701
    [Abstract] [Full Text] [Related]

  • 29. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y, Zhang Q, Cai CJ, Lu MQ, Li X, Jiang N, Jiang H, Xu C, Li H, Wang GS, Yi SH, Zhang J, Zhang JF, Yi HM, Zhang YC, Chen GH.
    Chin Med J (Engl); 2007 Aug 20; 120(16):1400-3. PubMed ID: 17825167
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL.
    Antivir Ther; 2008 Aug 20; 13(4):547-54. PubMed ID: 18672533
    [Abstract] [Full Text] [Related]

  • 32. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA, Buffello-Le Guillou D, Roche B, Dussaix E, Duclos-Vallée JC, Féray C, Samuel D.
    J Med Virol; 2001 Nov 20; 65(3):493-504. PubMed ID: 11596084
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
    Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R.
    Gut; 2002 Oct 20; 51(4):597-9. PubMed ID: 12235087
    [Abstract] [Full Text] [Related]

  • 36. How will we use the new antiviral agents for hepatitis B?
    Perrillo RP.
    Curr Gastroenterol Rep; 2002 Feb 20; 4(1):63-71. PubMed ID: 11825543
    [Abstract] [Full Text] [Related]

  • 37. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG, Suyanı E, Özenirler S, Sucak GT.
    Transplant Proc; 2013 Mar 20; 45(2):833-4. PubMed ID: 23498831
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
    Wolters LM, Honkoop P, Niesters HG, de Man RA.
    J Hepatol; 1998 May 20; 28(5):909-10. PubMed ID: 9625328
    [No Abstract] [Full Text] [Related]

  • 39. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation.
    Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR.
    Transplantation; 1997 May 27; 63(10):1415-9. PubMed ID: 9175803
    [Abstract] [Full Text] [Related]

  • 40. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation.
    Rayes N, Seehofer D, Bechstein WO, Müller AR, Berg T, Neuhaus R, Neuhaus P.
    Clin Transplant; 1999 Dec 27; 13(6):447-52. PubMed ID: 10617232
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.